June 30, 2020 / 11:30 AM / 4 days ago

BRIEF-Zynerba Pharmaceuticals Announces Top Line Results From Pivotal Connect-FX Trial Of Zygel

June 30 (Reuters) - Zynerba Pharmaceuticals Inc:

* ZYNERBA PHARMACEUTICALS ANNOUNCES TOP LINE RESULTS FROM PIVOTAL CONNECT-FX TRIAL OF ZYGEL™ (CBD GEL) IN FRAGILE X SYNDROME

* ZYNERBA PHARMACEUTICALS INC - STUDY DID NOT ACHIEVE STATISTICAL SIGNIFICANCE IN PRIMARY OR KEY SECONDARY ENDPOINTS IN FULL ANALYSIS SET Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below